Bullseye study

Recruiting

• Conditions: Inflammatory Bowel Diseases; Crohn's Disease; Ziekte van Crohn; Chronische darmontsteking; Inflammatoire darmziekten; vedolizumab; Entyvio; systems medicine

• Registration Number: NL-OMON25877
• Lead Sponsor: MC Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 65

Inclusion Criteria

Adult CD patients with luminal disease, who are anti-TNF therapy naïve, with an indication for step-up to vedolizumab will be recruited.

Exclusion Criteria

- No consent to participate in the study

- Hospitalized patients or patients in need of surgery

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To identify biomarkers predicting response to vedolizumab in patients with CD

Secondary Outcome Measures

Name	Time	Method
To gain insight in pathways, associated with (non)reponse to vedolizumab in patients with CD